76 completed. 76 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 76 | Completed 76 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thoracoscopic Talc Pleurodesis Versus Bleomycin -Tranxemic Acid Mixture Injection in Chest Tube in Malignant Pleural Effusion thoracoscope - Malignant Pleural Effusions (Mpe)- Pleurodesis, Pleurodesis | Phase 4 | Completed | Mohamed Sabry | 60 | 2024-09-01 | 2024-12-20 |
| Nebulized Lidocaine And Ketamine Before Fiberoptic Bronchoscopy Nebulized lidocaine and ketamine, Nebulized Lidocaine, Lidocaine spray (2%) - Fiberoptic Bronchoscopy (FOB), Lung Cancer (Diagnosis) | Phase 4 | Completed | Alexandria University | 134 | 2024-09-01 | 2026-08-03 |
| Rivaroxaban Sotorasib Interaction Study Rivaroxaban 20mg, Sotorasib 960mg - Drug Drug Interaction Study | Phase 4 | Completed | Radboud University Medical Center | 21 | 2023-11-09 | 2024-04-30 |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. Capmatinib 150 mg, Capmatinib 200 mg - Non-Small Cell Lung Carcinoma | Phase 4 | Completed | Novartis Pharmaceuticals | 50 | 2022-09-03 | 2026-10-26 |
| Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Gene Profile explore - Advanced NSCLC | Phase 4 | Completed | AstraZeneca | 182 | 2022-02-25 | 2025-09-11 |
| Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study Trilaciclib - Extensive-stage Small-cell Lung Cancer | Phase 4 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 30 | 2021-08-11 | 2023-10-06 |
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations Dacomitinib - Metastatic Non Small Cell Lung Cancer | Phase 4 | Completed | Pfizer | 101 | 2020-08-27 | 2024-04-05 |
| Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] Atezolizumab Injection [Tecentriq] - Lung Neoplasm Malignant | Phase 4 | Completed | Chonnam National University Hospital | 100 | 2019-12-18 | 2023-02-08 |
| Prospective Clinicogenomic Program Blood Draw - Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC) | Phase 4 | Completed | Genentech, Inc. | 945 | 2019-12-13 | 2024-01-17 |
| Durvalumab Long-Term Safety and Efficacy Study Durvalumab - Solid Tumor | Phase 4 | Completed | AstraZeneca | 163 | 2019-09-05 | 2024-12-20 |
| Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block Dexmedetomidine Group, dexamethasone group, control group - Lung Cancer | Phase 4 | Completed | China Medical University, China | 154 | 2019-07-12 | 2019-11-20 |
| Osimertinib Study in Indian Patients Osimertinib - Non Small Cell Lung Cancer (NSCLC) | Phase 4 | Completed | AstraZeneca | 60 | 2019-04-18 | 2021-06-03 |
| Dose Individualization of Pemetrexed - IMPROVE-I Pemetrexed + oral folinic acid rescue - Non Small Cell Lung Cancer, Mesothelioma | Phase 4 | Completed | Radboud University Medical Center | 6 | 2019-02-01 | 2024-12-17 |
| Dose Individualization of Pemetrexed - IMPROVE-III Pemetrexed - Non Small Cell Lung Cancer, Mesothelioma | Phase 4 | Completed | Radboud University Medical Center | 10 | 2019-02-01 | 2022-05-10 |
| Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Melanoma | Phase 4 | Completed | Merck Sharp & Dohme LLC | 150 | 2019-01-31 | 2025-08-29 |
| Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC Shenlingcao Oral Liquid - Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant | Phase 4 | Completed | West China Hospital | 527 | 2018-11-05 | 2024-05-09 |
| Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX Pembrolizumab Injection - Metastatic Non-Small Cell Lung Carcinoma | Phase 4 | Completed | Samsung Medical Center | 50 | 2018-05-14 | 2024-12-03 |
| Study of Nivolumab for Advanced Cancers in India Nivolumab - Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma | Phase 4 | Completed | Bristol-Myers Squibb | 100 | 2018-03-06 | 2020-12-04 |
| Oncoxin® and Quality of Life in Cancer Patients ONCOXIN® - Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II | Phase 4 | Completed | Catalysis SL | 133 | 2017-11-01 | 2019-06-05 |
| A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Atezolizumab - Carcinoma, Non-Small-Cell Lung | Phase 4 | Completed | Hoffmann-La Roche | 619 | 2017-10-25 | 2025-01-23 |
Showing 20 of 76. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (46) · Lung Neoplasms (35) · Pleural Effusion, Malignant (5) · Small Cell Lung Carcinoma (4) · Stomach Neoplasms (4) · Breast Neoplasms (3) · Carcinoma (3) · Carcinoma, Renal Cell (3) · Esophageal Neoplasms (3) · Head and Neck Neoplasms (3) · Kidney Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Large Cell (2) · Hypopharyngeal Neoplasms (2)
Neoplasms by Site (76) · Respiratory Tract Diseases (76) · Respiratory Tract Neoplasms (75) · Neoplasms (74) · Lung Diseases (71) · Carcinoma, Bronchogenic (47) · Bronchial Neoplasms (46) · Lung Neoplasms (36) · Neoplasms by Histologic Type (15) · Neoplasms, Glandular and Epithelial (9) · Hemic and Lymphatic Diseases (8) · Pathological Conditions, Signs and Symptoms (8) · Urogenital Diseases (8) · Digestive System Diseases (7)
Erlotinib Hydrochloride (7) · Carboplatin (6) · Pemetrexed (6) · Cisplatin (5) · Paclitaxel (3) · Acetaminophen (2) · Afatinib (2) · Docetaxel (2) · Gefitinib (2) · Gemcitabine (2) · Midazolam (2) · Nivolumab (2) · Propofol (2) · Saline Solution (2) · Vinorelbine (2)
AstraZeneca (6) · Hoffmann-La Roche (6) · Novartis Pharmaceuticals (3) · Radboud University Medical Center (3) · Amgen (2) · Boehringer Ingelheim (2) · Bristol-Myers Squibb (2) · Eli Lilly and Company (2) · Sun Yat-sen University (2) · Taipei Veterans General Hospital, Taiwan (2) · Alexandria University (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliero, Universitaria Ospedali Riuniti (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Betta Pharmaceuticals Co., Ltd. (1)
China (15) · United States (14) · India (8) · Brazil (7) · Netherlands (7) · Switzerland (6) · Taiwan (6) · Germany (5) · Poland (5) · South Korea (5) · Argentina (4) · Denmark (4) · Egypt (4) · France (4) · Greece (4)
Daniel Franzen, MD (2) · Rob ter Heine, PhD (2) · Yuh-Min Chen, MD, PhD. (2) · Andre GS Leite, PhD (1) · Bee Wee, PhD (1) · David Jablons, MD (1) · Dean T Yamaguchi, MD, PhD (1) · Gary E Goodman, MD (1) · Hugh Hemmings, MD, PhD (1)
PMID 10735670, PMID 11506101, PMID 16211735, PMID 18165618, PMID 19349389, PMID 19664781, PMID 20118030, PMID 21266057, PMID 21439671, PMID 21775497, PMID 22241828, PMID 2245677, PMID 22512843, PMID 22681919, PMID 23475281, PMID 23733379, PMID 24255769, PMID 24778393, PMID 25359988, PMID 25546556, PMID 25855621, PMID 27117455, PMID 27566586, PMID 27614989, PMID 28535181, PMID 29270080, PMID 30013197, PMID 30082870, PMID 31299247, PMID 31641390, PMID 33300144, PMID 33737339, PMID 34181276, PMID 34611902, PMID 34791718, PMID 35048355, PMID 35343187, PMID 36053283, PMID 36450379, PMID 36725084, PMID 36871476, PMID 37230961, PMID 37962202, PMID 39323258, PMID 39868569, PMID 40421804, PMID 41326340, PMID 657853, PMID 8404160, PMID 9560538
2016 (2), 2004 (1), 2014 (1), 2017 (1), 2019 (1), R01CA091912 (1), U01CA063673 (1)